Topotecan in platinum-resistant epithelial ovarian cancer

KARABULUT B. , SEZGIN C., Terek M. C. , USLU R. , Sanli U. A. , Akman L. , ...Daha Fazla

CHEMOTHERAPY, cilt.51, ss.347-351, 2005 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 51 Konu: 6
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1159/000088959
  • Sayfa Sayıları: ss.347-351


Background: Topotecan has been emerged as a new promising anticancer drug for patients with ovarian cancer. Methods: In this study, patients who were treated with topotecan were reviewed retrospectively. A total of 26 patients was included the study. All patients had received platinum-based regimens previously. Topotecan was administered a dose of 1.5 mg/m(2) intravenously 30 min daily for 5 days and repeated every 21 days. Results: The response rates were 30% by CA-125 level and 29% in clinic evaluation. Median duration of response was 8 ( 3 - 15) months, median progression-free interval was 12 ( 4 - 30) months and median overall survival was 15 ( 4 - 36) months. Grade 3 - 4 neutropenia occurred in 58% of the patients (38% of the courses) and trombocytopenia in 29% of the patients (12% of the courses). Nonhematological toxicities were mild. There was no drug-related death. Conclusion: Topotecan is considered as a reasonable option for treatment of patients with platinum refractory recurrent ovarian cancer. Copyright (C) 2005 S. Karger AG, Basel.